These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 15217383)
1. Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease. Diguet E; Fernagut PO; Wei X; Du Y; Rouland R; Gross C; Bezard E; Tison F Eur J Neurosci; 2004 Jun; 19(12):3266-76. PubMed ID: 15217383 [TBL] [Abstract][Full Text] [Related]
2. Neuroprotective effect of nicotine against 3-nitropropionic acid (3-NP)-induced experimental Huntington's disease in rats. Tariq M; Khan HA; Elfaki I; Al Deeb S; Al Moutaery K Brain Res Bull; 2005 Sep; 67(1-2):161-8. PubMed ID: 16140176 [TBL] [Abstract][Full Text] [Related]
4. Neuroprotection in Parkinson models varies with toxin administration protocol. Anderson DW; Bradbury KA; Schneider JS Eur J Neurosci; 2006 Dec; 24(11):3174-82. PubMed ID: 17156378 [TBL] [Abstract][Full Text] [Related]
5. Broad neuroprotective profile of nicotinamide in different mouse models of MPTP-induced parkinsonism. Anderson DW; Bradbury KA; Schneider JS Eur J Neurosci; 2008 Aug; 28(3):610-7. PubMed ID: 18702732 [TBL] [Abstract][Full Text] [Related]
6. Neuroprotective effect of taurine in 3-nitropropionic acid-induced experimental animal model of Huntington's disease phenotype. Tadros MG; Khalifa AE; Abdel-Naim AB; Arafa HM Pharmacol Biochem Behav; 2005 Nov; 82(3):574-82. PubMed ID: 16337998 [TBL] [Abstract][Full Text] [Related]
7. Striatal dopamine level contributes to hydroxyl radical generation and subsequent neurodegeneration in the striatum in 3-nitropropionic acid-induced Huntington's disease in rats. Pandey M; Borah A; Varghese M; Barman PK; Mohanakumar KP; Usha R Neurochem Int; 2009 Nov; 55(6):431-7. PubMed ID: 19410615 [TBL] [Abstract][Full Text] [Related]
8. D(1) dopamine receptor agonists are more effective in alleviating advanced than mild parkinsonism in 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated monkeys. Goulet M; Madras BK J Pharmacol Exp Ther; 2000 Feb; 292(2):714-24. PubMed ID: 10640310 [TBL] [Abstract][Full Text] [Related]
9. Kaempferol protects against rat striatal degeneration induced by 3-nitropropionic acid. Lagoa R; Lopez-Sanchez C; Samhan-Arias AK; Gañan CM; Garcia-Martinez V; Gutierrez-Merino C J Neurochem; 2009 Oct; 111(2):473-87. PubMed ID: 19682208 [TBL] [Abstract][Full Text] [Related]
11. Age-related severity of dopaminergic neurodegeneration to MPTP neurotoxicity causes motor dysfunction in C57BL/6 mice. Ohashi S; Mori A; Kurihara N; Mitsumoto Y; Nakai M Neurosci Lett; 2006 Jun; 401(1-2):183-7. PubMed ID: 16581184 [TBL] [Abstract][Full Text] [Related]
12. Neuroprotective effects of genistein on dopaminergic neurons in the mice model of Parkinson's disease. Liu LX; Chen WF; Xie JX; Wong MS Neurosci Res; 2008 Feb; 60(2):156-61. PubMed ID: 18054104 [TBL] [Abstract][Full Text] [Related]
13. Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains. Haobam R; Sindhu KM; Chandra G; Mohanakumar KP Behav Brain Res; 2005 Sep; 163(2):159-67. PubMed ID: 15941598 [TBL] [Abstract][Full Text] [Related]
14. A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington's disease. Keene CD; Rodrigues CM; Eich T; Linehan-Stieers C; Abt A; Kren BT; Steer CJ; Low WC Exp Neurol; 2001 Oct; 171(2):351-60. PubMed ID: 11573988 [TBL] [Abstract][Full Text] [Related]
15. IGF-1 exacerbates the neurotoxicity of the mitochondrial inhibitor 3NP in rats. Escartin C; Boyer F; Bemelmans AP; Hantraye P; Brouillet E Neurosci Lett; 2007 Oct; 425(3):167-72. PubMed ID: 17868993 [TBL] [Abstract][Full Text] [Related]
16. Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson's disease. Kurkowska-Jastrzebska I; Litwin T; Joniec I; Ciesielska A; Przybyłkowski A; Członkowski A; Członkowska A Int Immunopharmacol; 2004 Oct; 4(10-11):1307-18. PubMed ID: 15313429 [TBL] [Abstract][Full Text] [Related]
17. Neuropathological and behavioral changes induced by various treatment paradigms with MPTP and 3-nitropropionic acid in mice: towards a model of striatonigral degeneration (multiple system atrophy). Stefanova N; Puschban Z; Fernagut PO; Brouillet E; Tison F; Reindl M; Jellinger KA; Poewe W; Wenning GK Acta Neuropathol; 2003 Aug; 106(2):157-66. PubMed ID: 12764627 [TBL] [Abstract][Full Text] [Related]
18. L-Dopa treatment abolishes the numerical increase in striatal dopaminergic neurons in parkinsonian monkeys. Huot P; Lévesque M; Morissette M; Calon F; Dridi M; Di Paolo T; Parent A J Chem Neuroanat; 2008 Jan; 35(1):77-84. PubMed ID: 17706922 [TBL] [Abstract][Full Text] [Related]
19. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Du Y; Ma Z; Lin S; Dodel RC; Gao F; Bales KR; Triarhou LC; Chernet E; Perry KW; Nelson DL; Luecke S; Phebus LA; Bymaster FP; Paul SM Proc Natl Acad Sci U S A; 2001 Dec; 98(25):14669-74. PubMed ID: 11724929 [TBL] [Abstract][Full Text] [Related]
20. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea. Huot P; Lévesque M; Parent A Brain; 2007 Jan; 130(Pt 1):222-32. PubMed ID: 17142832 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]